US 11660274
Dosage forms and methods for enantiomerically enriched or pure bupropion
granted A61KA61K31/137A61K9/0053
Quick answer
US patent 11660274 (Dosage forms and methods for enantiomerically enriched or pure bupropion) held by AXSOME THERAPEUTICS, INC. expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- AXSOME THERAPEUTICS, INC.
- Grant date
- Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/137, A61K9/0053, A61K9/006, A61K9/0095